(Insulin aspart + insulin aspart protamine) is a Recombinant Protein owned by Novo Nordisk, and is involved in 105 clinical trials, which were completed.

Insulin aspart protamine and insulin aspart is a replacement insulin that acts in same way as naturally produced insulin. The primary activity of insulin aspart protamine is the regulation of glucose metabolism. Insulins, including insulin aspart protamine, bind to the insulin receptors on muscle, liver and fat cells and lower blood glucose by facilitating the cellular uptake of glucose and simultaneously inhibiting the output of glucose from the liver. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis, and enhances protein synthesis.

The revenue for (Insulin aspart + insulin aspart protamine) is expected to reach a total of $17.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Insulin aspart + insulin aspart protamine) NPV Report.

(Insulin aspart + insulin aspart protamine) is currently owned by Novo Nordisk.

(Insulin aspart + insulin aspart protamine) Overview

Human insulin (NovoLog Mix 70/30 / Novomix / NovoMix 30 Penfill / NovoMix 30 FlexPen / NovoMix 30 FlexPen / Novolog Mix 50/50 / NovoMix 70 Penfill / NovoLog Mix 70/30 Flexpen / NovoLog Mix 70/30 Penfill / NovoMix 50 FlexPen / NovoMix 70 FlexPen / NovoMix 50 Penfill / NovoMix Penfill )  is a fixed dose combination product it is a analog comprising of 70% insulin aspart protamine crystals and 30% soluble insulin aspart. Insulin aspart is produced by employing recombinant DNA technology on saccharomyces cerevisiae (baker's yeast). Insulin aspart is homologous with regular human insulin except for amino acid proline that is replaced by aspartic acid in position B28. It is formulated as injection suspension for subcutaneous route of administration. It is indicated for improving glycemic control in adults as well as children with diabetes mellitus.

Novo Nordisk Overview

Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing of innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. the company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

The company reported revenues of (Danish Krone) DKK140,800 million for the fiscal year ended December 2021 (FY2021), an increase of 10.9% over FY2020. In FY2021, the company’s operating margin was 41.7%, compared to an operating margin of 42.6% in FY2020. In FY2021, the company recorded a net margin of 33.9%, compared to a net margin of 33.2% in FY2020. The company reported revenues of DKK45,566 million for the third quarter ended September 2022, an increase of 10.4% over the previous quarter.

Quick View – (Insulin aspart + insulin aspart protamine)

Report Segments
  • Innovator (NME)
Drug Name
  • (Insulin aspart + insulin aspart protamine)
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.